RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy

Dermatology Research and Practice

Volumn 2012, Issue , 2012, Pages

  Yajima, Ichiro ^a   Kumasaka, Mayuko Y ^a   Thang, Nguyen Dinh ^a   Goto, Yuji ^a   Takeda, Kozue ^a   Yamanoshita, Osamu ^a   Iida, Machiko ^a   Ohgami, Nobutaka ^a   Tamura, Haruka ^a   Kawamoto, Yoshiyuki ^a   Kato, Masashi ^a  

^a CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEUROTROPHIC FACTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR; STEM CELL FACTOR; VEMURAFENIB;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER INVASION; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; GENE ACTIVATION; GENE CONTROL; GENE MUTATION; GLIA CELL; HUMAN; MELANOMA; REVIEW; SIGNAL TRANSDUCTION;

EID: 84867539636     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2012/354191     Document Type: Review

References (67)

1. Helfrich I., Scheffrahn I., Bartling S., Weis J., Von Felbert V., Middleton M., Kato M., Ergün S., Schadendorf D., Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. Journal of Experimental Medicine 2010 207 3 491 503 2-s2.0-77949494504 10.1084/jem.20091846
2. Kato M., Hattori T., Ito H., Kageyama M., Yamashita T., Nitta Y., Nakashima I., Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis. Journal of Allergy and Clinical Immunology 1999 103 6 1213 1214 2-s2.0-0032837720 10.1016/S0091-6749(99)70202-2 (Pubitemid 29343093)
3. Liu W., Kato M., Akhand A. A., Hayakawa A., Suzuki H., Miyata T., Kurokawa K., Hotta Y., Ishikawa N., Nakashima I., 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. Journal of Cell Science 2000 113, part 4 635 641 2-s2.0-0034098451 (Pubitemid 30133041)
4. Ohshima Y., Yajima I., Takeda K., Iida M., Kumasaka M., Matsumoto Y., Kato M., c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS ONE 2010 5 4 2-s2.0-77955350230 10.1371/journal.pone.0010279 e10279
5. Kato M., Takeda K., Kawamoto Y., Iwashita T., Akhand A. A., Senga T., Yamamoto M., Sobue G., Hamaguchi M., Takahashi M., Nakashima I., Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. Cancer Research 2002 62 8 2414 2422 2-s2.0-0037089461 (Pubitemid 34411726)
6. Kato M., Takeda K., Kawamoto Y., Tsuzuki T., Dai Y., Nakayama S., Toriyama K., Tamada Y., Takahashi M., Nakashima I., RET tyrosine kinase enhances hair growth in association with promotion of melanogenesis. Oncogene 2001 20 51 7536 7541 2-s2.0-0035829742 10.1038/sj.onc.1204918 (Pubitemid 33086913)
7. Kato M., Wickner W., Vam10p defines a Sec18p-independent step of priming that allows yeast vacuole tethering. Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6398 6403 2-s2.0-0038313089 10.1073/pnas.1132162100 (Pubitemid 36666593)
8. Hossain K., Akhand A. A., Kato M., Du J., Takeda K., Wu J., Takeuchi K., Liu W., Suzuki H., Nakashima I., Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase. Journal of Immunology 2000 165 8 4290 4297 2-s2.0-0034668012
9. Kato M., Iwashita T., Akhand A. A., Liu W., Takeda K., Takeuchi K., Yoshihara M., Hossain K., Wu J., Du J., Oh C., Kawamoto Y., Suzuki H., Takahashi M., Nakashima I., Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation. Antioxidants and Redox Signaling 2000 2 4 841 849 2-s2.0-0034534534 (Pubitemid 32062333)
10. Kato M., Iwashita T., Takeda K., Akhand A. A., Liu W., Yoshihara M., Asai N., Suzuki H., Takahashi M., Nakashima I., Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases. Molecular Biology of the Cell 2000 11 1 93 101 2-s2.0-0033973130 (Pubitemid 30075508)
11. Ohgami N., Ida-Eto M., Shimotake T., Sakashita N., Sone M., Nakashima T., Tabuchi K., Hoshino T., Shimada A., Tsuzuki T., Yamamoto M., Sobue G., Jijiwa M., Asai N., Hara A., Takahashi M., Kato M., C-Ret-mediated hearing loss in mice with Hirschsprung disease. Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13051 13056 2-s2.0-77955649682 10.1073/pnas.1004520107
12. Ohgami N., Kondo T., Kato M., katomasa@isc.chubu.ac.jp Effects of light smoking on extra-high-frequency auditory thresholds in young adults. Toxicology and Industrial Health 2011 27 2 143 147 10.1177/0748233710382539
13. Blois M. S., Vitamin D, sunlight, and natural selection. Science 1968 159 815 652 2-s2.0-0014407224
14. Kamei S., Yajima I., Yamamoto H., Kobayashi A., Makabe K. W., Yamazaki H., Hayashi S. I., Kunisada T., Characterization of a novel member of the FGFR family, HrFGFR, in Halocynthia roretzi. Biochemical and Biophysical Research Communications 2000 275 2 503 508 2-s2.0-0034726677 10.1006/bbrc.2000.3334
15. Kumasaka M., Sato S., Yajima I., Goding C. R., Yamamoto H., Regulation of melanoblast and retinal pigment epithelium development by Xenopus laevis Mitf. Developmental Dynamics 2005 234 3 523 534 2-s2.0-27444440806 10.1002/dvdy.20505 (Pubitemid 41532975)
16. Kumasaka M., Sato S., Yajima I., Yamamoto H., Isolation and developmental expression of tyrosinase family genes in Xenopus laevis. Pigment Cell Research 2003 16 5 455 462 2-s2.0-0042337134 10.1034/j.1600-0749.2003.00064.x (Pubitemid 37093020)
17. Sato S., Toyoda R., Katsuyama Y., Saiga H., Numakunai T., Ikeo K., Gojobori T., Yajima I., Yamamoto H., Structure and developmental expression of the ascidian TRP gene: insights into the evolution of pigment cell-specific gene expression. Developmental Dynamics 1999 215 3 225 237 2-s2.0-0032995671 10.1002/(SICI)1097-0177(199907)215:3225::AID-AJA5>3.0.CO;2-S (Pubitemid 29310070)
18. Yajima I., Endo K., Sato S., Toyoda R., Wada H., Shibahara S., Numakunai T., Ikeo K., Gojobori T., Goding C. R., Yamamoto H., Cloning and functional analysis of ascidian Mitf in vivo: insights into the origin of vertebrate pigment cells. Mechanisms of Development 2003 120 12 1489 1504 2-s2.0-0345707673 10.1016/j.mod.2003.08.009 (Pubitemid 37488036)
19. Yajima I., Larue L., The location of heart melanocytes is specified and the level of pigmentation in the heart may correlate with coat color. Pigment Cell and Melanoma Research 2008 21 4 471 476 2-s2.0-47249135101 10.1111/j.1755-148X.2008.00483.x (Pubitemid 351990973)
20. Puig I., Yajima I., Bonaventure J., Delmas V., Larue L., The tyrosinase promoter is active in a subset of vagal neural crest cells during early development in mice. Pigment Cell and Melanoma Research 2009 22 3 331 334 2-s2.0-65549113888 10.1111/j.1755-148X.2009.00546.x
21. Tsukiji N., Nishihara D., Yajima I., Takeda K., Shibahara S., Yamamoto H., Mitf functions as an in ovo regulator for cell differentiation and proliferation during development of the chick RPE. Developmental Biology 2009 326 2 335 346 2-s2.0-58649120786 10.1016/j.ydbio.2008.11.029
22. Yajima I., Sato S., Kimura T., Yasumoto K. I., Shibahara S., Goding C. R., Yamamoto H., An L1 element intronic insertion in the black-eyed white (Mitf(mi-bw)) gene: the loss of a single Mitf isoform responsible for the pigmentary defect and inner ear deafness. Human Molecular Genetics 1999 8 8 1431 1441 2-s2.0-0032815964 10.1093/hmg/8.8.1431 (Pubitemid 29374076)
23. Chiang J. M., Chou Y. H. W., Ma S. C., Chen J. R., Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-Rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. Virchows Archiv 2004 445 5 465 471 2-s2.0-9944227795 10.1007/s00428-004-1116-z (Pubitemid 39592749)
24. Hede S. M., Hansson I., Afink G. B., Eriksson A., Nazarenko I., Andrae J., Genove G., Westermanrk B., Nistér M., GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. GLIA 2009 57 11 1143 1153 2-s2.0-69649103118 10.1002/glia.20837
25. Olschwang S., Hamelin R., Laurent-Puig P., Thuille B., De Rycke Y., Li Y. J., Muzeau F., Girodet J., Salmon R. J., Thomas G., Alternative genetic pathways in colorectal carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 1997 94 22 12122 12127 2-s2.0-12644274663 10.1073/pnas.94.22.12122 (Pubitemid 27467853)
26. Zhu H., Acquaviva J., Ramachandran P., Boskovitz A., Woolfenden S., Pfannl R., Bronson R. T., Chen J. W., Weissleder R., Housman D. E., Charest A., Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2712 2716 2-s2.0-62449252775 10.1073/pnas. 0813314106
27. Friedman R. J., Rigel D. S., Kopf A. W., Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Archives of Dermatology 1983 119 6 455 462 2-s2.0-0020505245 10.1001/archderm.119.6.455 (Pubitemid 13100107)
28. Kaddu S., Smolle J., Zenahlik P., Hofmann-Wellenhof R., Kerl H., Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Research 2002 12 3 271 278 2-s2.0-0035999097 10.1097/00008390-200206000-00011 (Pubitemid 34666818)
29. Weatherhead S. C., Haniffa M., Lawrence C. M., Melanomas arising from naevi and de novo melanomas-does origin matter? British Journal of Dermatology 2007 156 1 72 76 2-s2.0-33845535111 10.1111/j.1365-2133.2006.07570.x (Pubitemid 44924147)
30. Kato M., Takahashi M., Akhand A. A., Liu W., Dai Y., Shimizu S., Iwamoto T., Suzuki H., Nakashima I., Transgenic mouse model for skin malignant melanoma. Oncogene 1998 17 14 1885 1888 2-s2.0-0032497642 (Pubitemid 28482792)
31. Kato M., Takeda K., Kawamoto Y., Tsuzuki T., Hossain K., Tamakoshi A., Kunisada T., Kambayashi Y., Ogino K., Suzuki H., Takahashi M., Nakashima I., c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Research 2004 64 3 801 806 2-s2.0-10744232280 10.1158/0008-5472.CAN-03-2532 (Pubitemid 38176874)
32. Kumasaka M. Y., Yajima I., Hossain K., Iida M., Tsuzuki T., Ohno T., Takahashi M., Yanagisawa M., Kato M., A novel mouse model for de novo melanoma. Cancer Research 2010 70 1 24 29 2-s2.0-75149129051 10.1158/0008-5472.CAN-09-2838
33. Ohshima Y., Yajima I., Kumasaka M. Y., Yanagishita T., Watanabe D., Takahashi M., Inoue Y., Ihn H., Matsumoto Y., Kato M., CD109 expression levels in malignant melanoma. Journal of Dermatological Science 2010 57 2 140 142 2-s2.0-74749097708 10.1016/j.jdermsci.2009.11.004
34. Yajima I., Kumasaka M., Thang N. D., Yanagishita T., Ohgami N., Kallenberg D., Naito Y., Yoshikawa T., Sakashita N., Kato M., Zinc finger protein 28 as a novel melanoma-related molecule. Journal of Dermatological Science 2009 55 1 68 70 2-s2.0-67349128973 10.1016/j.jdermsci.2009.02.010
35. Goodall J., Wellbrock C., Dexter T. J., Roberts K., Marais R., Goding C. R., The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Molecular and Cellular Biology 2004 24 7 2923 2931 2-s2.0-1642277009 10.1128/MCB.24.7.2923-2931.2004 (Pubitemid 38381281)
36. Gray-Schopfer V., Wellbrock C., Marais R., Melanoma biology and new targeted therapy. Nature 2007 445 7130 851 857 2-s2.0-33847220364 10.1038/nature05661
37. Bohm M., Moellmann G., Cheng E., Alvarez-Franco M., Wagner S., Sassone-Corsi P., Halaban R., Identification of p90(RSK) as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth and Differentiation 1995 6 3 291 302 2-s2.0-0028986124
38. Narita N., Tanemura A., Murali R., Scolyer R. A., Huang S., Arigami T., Yanagita S., Chong K. K., Thompson J. F., Morton D. L., Hoon D. S., Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009 28 34 3058 3068 2-s2.0-69449087581 10.1038/onc.2009.164
39. Cohen C., Zavala-Pompa A., Sequeira J. H., Shoji M., Sexton D. G., Cotsonis G., Cerimele F., Govindarajan B., Macaron N., Arbiser J. L., Mitogen-actived protein kinase activation is an early event in melanoma progression. Clinical Cancer Research 2002 8 12 3728 3733 2-s2.0-0036896253 (Pubitemid 35424762)
40. Satyamoorthy K., Li G., Gerrero M. R., Brose M. S., Volpe P., Weber B. L., Van Belle P., Elder D. E., Herlyn M., Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research 2003 63 4 756 759 2-s2.0-0037442752 (Pubitemid 36231971)
41. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmleri G., Cossu A., Flanagan A., Nicholson A., Ho J. W. C., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., Futreal P. A., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 2-s2.0-18444374405 10.1038/nature00766 (Pubitemid 34716871)
42. Gray-Schopfer V. C., da Rocha Dias S., Marais R., The role of B-RAF in melanoma. Cancer and Metastasis Reviews 2005 24 1 165 183 2-s2.0-17744388986 10.1007/s10555-005-5865-1 (Pubitemid 40576070)
43. Sharma A., Trivedi N. R., Zimmerman M. A., Tuveson D. A., Smith C. D., Robertson G. P., Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research 2005 65 6 2412 2421 2-s2.0-16844362816 10.1158/0008-5472.CAN-04-2423 (Pubitemid 40490153)
44. Dhawan P., Richmond A., A novel NF- κ B-inducing kinase-MAPK signaling pathway up-regulates NF- κ B activity in melanoma cells. Journal of Biological Chemistry 2002 277 10 7920 7928 2-s2.0-0037040901 10.1074/jbc.M112210200 (Pubitemid 34968242)
45. Liu J., Suresh Kumar K. G., Yu D., Molton S. A., McMahon M., Herlyn M., Thomas-Tikhonenko A., Fuchs S. Y., Oncogenic BRAF regulates β -Trcp expression and NF- κ B activity in human melanoma cells. Oncogene 2007 26 13 1954 1958 2-s2.0-33947527353 10.1038/sj.onc.1209994 (Pubitemid 46474640)
46. Bennett D. C., How to make a melanoma: what do we know of the primary clonal events? Pigment Cell and Melanoma Research 2008 21 1 27 38 2-s2.0-41049114747 10.1111/j.1755-148X.2007.00433.x (Pubitemid 351421467)
47. Maehama T., Dixon J. E., PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends in Cell Biology 1999 9 4 125 128 2-s2.0-0032904432 10.1016/S0962-8924(99)01519-6 (Pubitemid 29161437)
48. Dhawan P., Singh A. B., Ellis D. L., Richmond A., Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor- κ B and tumor progression. Cancer Research 2002 62 24 7335 7342 2-s2.0-0037115394 (Pubitemid 36025257)
49. Kim D., Kim S., Koh H., Yoon S. O., Chung A. S., Cho K. S., Chung J., Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB Journal 2001 15 11 1953 1962 2-s2.0-0034852195 10.1096/fj.01-0198com (Pubitemid 32848799)
50. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M., The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience 2005 10 3 2986 3001 2-s2.0-21344456180 (Pubitemid 40910537)
51. Park B. K., Zeng X., Glazer R. I., Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Research 2001 61 20 7647 7653 2-s2.0-0035887436 (Pubitemid 32995061)
52. Sekulic A., Haluska P. Jr., Miller A. J., De Lamo J. G., Ejadi S., Pulido J. S., Salomao D. R., Thorland E. C., Vile R. G., Swanson D. L., Pockaj B. A., Laman S. D., Pittelkow M. R., Markovic S. N., Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clinic Proceedings 2008 83 7 825 846 2-s2.0-46749143660 10.4065/83.7.825 (Pubitemid 351948695)
53. Polsky D., Melzer K., Hazen C., Kamino H., Spira J. G., Kopf A. W., Perelman R. O., Osman I., Panageas K. S., Busan K., Drobnjak M., Cordon-Cardo C., Houghton A., HDM2 protein overexpression and prognosis in primary malignant melanoma. Journal of the National Cancer Institute 2002 94 23 1803 1806 2-s2.0-0037021660 (Pubitemid 36004356)
54. Mayo L. D., Donner D. B., A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11598 11603 2-s2.0-0035949588 10.1073/pnas.181181198 (Pubitemid 32928774)
55. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y., Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Journal of Biological Chemistry 2002 277 24 21843 21850 2-s2.0-0037077230 10.1074/jbc.M109745200 (Pubitemid 34952337)
56. Zhou B. P., Liao Y., Xia W., Zou Y., Spohn B., Hung M. C., HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biology 2001 3 11 973 982 2-s2.0-0035736487 10.1038/ncb1101-973 (Pubitemid 34428742)
57. Hainsworth J. D., Infante J. R., Spigel D. R., Peyton J. D., Thompson D. S., Lane C. M., Clark B. L., Rubin M. S., Trent D. F., Burris H. A., Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010 116 17 4122 4129 2-s2.0-77956839364 10.1002/cncr.25320
58. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P. N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E. A., Wong B., Tsang G., West B. L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K. Y. J., Artis D. R., Schlessinger J., Su F., Higgins B., Iyer R., Dandrea K., Koehler A., Stumm M., Lin P. S., Lee R. J., Grippo J., Puzanov I., Kim K. B., Ribas A., McArthur G. A., Sosman J. A., Chapman P. B., Flaherty K. T., Xu X., Nathanson K. L., Nolop K., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 467 7315 596 599 2-s2.0-77956513286 10.1038/nature09454
59. Chapman P. B., chapmanp@mskcc.org Hauschild A., Robert C., Haanen J. B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S. J., Sosman J. A., Kirkwood J. M., Eggermont A. M.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R. J., Flaherty K. T., McArthur G. A., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 2011 364 26 2507 2516 10.1056/NEJMoa1103782
60. Flaherty K. T., Puzanov I., Kim K. B., Ribas A., McArthur G. A., Sosman J. A., O'Dwyer P. J., Lee R. J., Grippo J. F., Nolop K., Chapman P. B., Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 2010 363 9 809 819 2-s2.0-77956030786 10.1056/NEJMoa1002011
61. Arkenau H. T., Kefford R., Long G. V., Targeting BRAF for patients with melanoma. British Journal of Cancer 2011 104 3 392 398 2-s2.0-78649700118 10.1038/sj.bjc.6606030
62. Johannessen C. M., Boehm J. S., Kim S. Y., Thomas S. R., Wardwell L., Johnson L. A., Emery C. M., Stransky N., Cogdill A. P., Barretina J., Caponigro G., Hieronymus H., Murray R. R., Salehi-Ashtiani K., Hill D. E., Vidal M., Zhao J. J., Yang X., Alkan O., Kim S., Harris J. L., Wilson C. J., Myer V. E., Finan P. M., Root D. E., Roberts T. M., Golub T., Flaherty K. T., Dummer R., Weber B. L., Sellers W. R., Schlegel R., Wargo J. A., Hahn W. C., Garraway L. A., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 468 7326 968 972 2-s2.0-78650309875 10.1038/nature09627
63. Nazarian R., Shi H., Wang Q., Kong X., Koya R. C., Lee H., Chen Z., Lee M. K., Attar N., Sazegar H., Chodon T., Nelson S. F., McArthur G., Sosman J. A., Ribas A., Lo R. S., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 468 7326 973 977 2-s2.0-78650303507 10.1038/nature09626
64. Poulikakos P. I., Rosen N., Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2010 19 1 11 15
65. Villanueva J., Vultur A., Lee J. T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A. K., Wubbenhorst B., Xu X., Gimotty P. A., Kee D., Santiago-Walker A. E., Letrero R., D'Andrea K., Pushparajan A., Hayden J. E., Brown K. D., Laquerre S., McArthur G. A., Sosman J. A., Nathanson K. L., Herlyn M., Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010 18 6 683 695 2-s2.0-78650008177 10.1016/j.ccr.2010.11.023
66. Croghan G. A., Suman V. J., Maples W. J., Albertini M., Linette G., Flaherty L., Eckardt J., Ma C., Markovic S. N., Erlichman C., A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer 2010 116 14 3463 3468 2-s2.0-77954897621 10.1002/cncr.25191
67. Markovic S. N., Geyer S. M., Dawkins F., Sharfman W., Albertini M., Maples W., Fracasso P. M., Fitch T., LoRusso P., Adjei A. A., Erlichman C., A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005 103 12 2584 2589 2-s2.0-20444364475 10.1002/cncr.21108 (Pubitemid 40800538)